A Prospective Randomized Controlled Trial Assessing the Efficacy of Withdrawing Alpha-blocker Following Initial Combination Therapy with 5-Alpha Reductase Inhibitor for Benign Prostatic Hyperplasia
Not Applicable
Completed
- Conditions
- Benign Prostate HyperplasiaRenal and Urogenital - Other renal and urogenital disorders
- Registration Number
- ACTRN12612000853842
- Lead Sponsor
- niversiti Kebangsaan Malaysia Medical Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 102
Inclusion Criteria
patients with moderate or severe BPH based on IPSS score who were newly diagnosed and started on combination therapy or who were previously diagnosed and were already on combination therapy for a duration of not more than one year. All patients on combination therapy had a prostate size of more than 40g as assessed by digital rectal examination
Exclusion Criteria
All patients had a baseline PSA taken routinely and patients with a value higher than 4ng/ml underwent biopsy to screen for possible malignancy. Patients with PSA value less than 1.5ng/ml, prostate cancer and patients with recurrent urinary tract infections were excluded from our study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method International Prostate Symptoms Score[Basline and 3 months]
- Secondary Outcome Measures
Name Time Method Maximal urinary Flow Rate via uroflowmeter equipment[baseline and 3 months]